Cronos Group Inc vs Nebius Group NV — how do they compare? Cronos Group Inc trades at $3.08 (market cap $1.11B), while Nebius Group NV trades at $211.5 (market cap $46.75B). The key difference: Nebius Group NV is far larger — about 42.1× Cronos Group Inc's market cap, and Cronos Group Inc is trading nearer its 52-week high, Nebius Group NV nearer its low. Which is the better fit depends on your goals.
| CRON | NBIS | |
|---|---|---|
Market Cap | $1.11B | $46.75B |
Sector | Health | Technology |
52-Week High | $3.27 | $286.69 |
52-Week Low | $2.30 | $64.06 |
Enterprise Value | $310.67M | $46.94B |
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.10 with a 0.98% daily gain, showing bullish technical momentum. The company delivered strong Q2 2026 results with 58% YoY revenue growth and earnings beat, while maintaining #1 market share in Canadian vapes and edibles. Despite negative net income in 2025, revenue growth accelerated to $147M with improving margins. Technical indicators show bullish moving averages but RSI suggests potential overbought conditions near $3 resistance.
Outlook remains positive with international expansion and European cannabis legalization driving growth, though competitive pressures and execution risks persist. Analyst consensus is mixed with 60% hold ratings, reflecting cautious optimism about CRON's turnaround trajectory from previous losses to projected 39% profit margin by 2026.
NBIS trades at $187.97, down 1.01% with a bearish technical signal despite strong analyst support. The stock shows extreme valuation multiples (P/E 71.08, P/S 55.67) while demonstrating explosive revenue growth projections from $530M in 2025 to $878M in 2026. Recent earnings have been mixed with Q1 2026 beating expectations but Q4 2025 missing, with Q2 2026 results pending. The company faces significant execution risk as it scales AI infrastructure amid substantial capital expenditures.
The investment case hinges on NBIS converting its $1.9B annual run rate and contracted backlog into profitable growth. While analyst consensus remains strongly bullish with a $248.73 price target, high valuation and Michael Burry's short position highlight execution risks. Success depends on managing capex intensity and demonstrating operating leverage in upcoming earnings.
Trailing returns across standard periods
Latest headlines on both assets
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →